About: Morphine/naltrexone

An Entity of Type: combination drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

The drug combination morphine/naltrexone (trade name Embeda) is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule 2 controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.

Property Value
dbo:abstract
  • The drug combination morphine/naltrexone (trade name Embeda) is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule 2 controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated. King Pharmaceuticals temporarily recalled Embeda in 2011 after complaints from the FDA in regard to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential. Embeda became available again some years later. (en)
dbo:alternativeName
  • Embeda (en)
dbo:casNumber
  • 1131418-84-2
dbo:wikiPageID
  • 25012978 (xsd:integer)
dbo:wikiPageLength
  • 2858 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1082990821 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1131418 (xsd:integer)
dbp:class
dbp:component
  • Naltrexone (en)
  • Morphine sulfate (en)
dbp:legalUs
  • Schedule II (en)
dbp:pregnancyUs
  • C (en)
dbp:routesOfAdministration
  • Oral (en)
dbp:tradename
  • Embeda (en)
dbp:type
  • combo (en)
dbp:verifiedrevid
  • 416646931 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • The drug combination morphine/naltrexone (trade name Embeda) is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule 2 controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated. (en)
rdfs:label
  • Morphine/naltrexone (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License